Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo (Q40477055)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo |
scientific article |
Statements
1 reference
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo (English)
1 reference
M Martín
1 reference
A Lluch
1 reference
M A Seguí
1 reference
A Ruiz
1 reference
M Ramos
1 reference
E Adrover
1 reference
A Rodríguez-Lescure
1 reference
R Grosse
1 reference
L Calvo
1 reference
C Fernandez-Chacón
1 reference
M Roset
1 reference
A Antón
1 reference
D Isla
1 reference
P Martínez del Prado
1 reference
L Iglesias
1 reference
J Zaluski
1 reference
A Arcusa
1 reference
J M López-Vega
1 reference
M Muñoz
1 reference
J R Mel
1 reference
9 June 2006
1 reference
1 reference
17
1 reference
8
1 reference
1205-1212
1 reference
Identifiers
1 reference
1 reference